203302-73-2

Basic information

• Product Name: 1H-Benzimidazol-5-amine,2-chloro-(9CI)
• Synonyms: 1H-Benzimidazol-5-amine,2-chloro-(9CI);2-chloro-1H-benzo[d]imidazol-5-amine;2-chloro-1(3)H-benzoimidazol-5-ylamine
• CAS NO: 203302-73-2
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.59564
• Product Categories: BENZIMIDAZOLE
• Mol File: 203302-73-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazol-5-amine,2-chloro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazol-5-amine,2-chloro-(9CI)(203302-73-2)
• EPA Substance Registry System: 1H-Benzimidazol-5-amine,2-chloro-(9CI)(203302-73-2)

Safety Data

• Hazardous Substances Data: 203302-73-2(Hazardous Substances Data)

Usage

Structure

Aromatic amine with a benzimidazole core and a chlorine substituent at the 2-position

Usage

Commonly used in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Biological activities

Studied for its potential anti-cancer and anti-inflammatory properties

Chemical reactivity

The presence of a chlorine atom can affect its interactions with other molecules, making it a valuable building block in chemical compound development

Hazards and health risks

Should be handled and used with caution due to potential hazards and health risks.

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 5955-72-6 2-chloro-5-nitro-1H-benzo[d]imidazole 

Downstream Products

• 85561-97-3 1H-benzo[d]imidazole-2,5-diamine 
• 832102-62-2 N²-methyl-1H-benzoimidazole-2,5-diamine 
• 462649-02-1 N₂,N₂-dimethyl-1H-benzo[d]imidazol-2,5-diamine 
• 203302-76-5 N-(2-chlorobenzimidazol-5-yl)anthranilic acid 

Relevant articles and documents

COMPOUNDS FOR TREATING RESPIRATORY DISEASE

Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: Formula (I), wherein (AA) represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are as defined herein; are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.

Novel benzimidazole-based MCH R1 antagonists

The identification of an MCH R1 antagonist screening hit led to the optimization of a class of benzimidazole-based MCH R1 antagonists. Structure-activity relationships and efforts to optimize pharmacokinetic properties are detailed along with the demonstration of the effectiveness of an MCH R1 antagonist in an animal model of obesity.

Pyridinium Betaines Derived from Thiazolo and Imidazoacridinones

Four betaines derived from imidazo[4,5-a], imidazo[5,4-a] and thiazolo[5,4-a]acridine have been prepared in a six step procedure starting from 2-chlorobenzimidazoles and benzothiazoles. The 1H and 133C nmr has been used to characteri